Oncology News | pharmaphorum

News

Scrabble letters spelling out 'Learn from failure'

Daiichi and AZ pull Dato-DXd filing with FDA and try again

Nine months after filing their TROP2-directed antibody-drug conjugate Dato-DXd for a lung cancer indication with the FDA, Daiichi Sankyo and AstraZeneca have pulled the submission.

News

23andMe ends drug development and slashes staff

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses.

News

window into laboratory with scientist hard at work

Autolus bags FDA approval for leukaemia cell therapy

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with aggressive blood cancer acute lymphoblastic leukaemia (ALL).

News

J&J bids to add smouldering myeloma to Darzalex label

Johnson & Johnson has reported positive phase 3 data with Darzalex in smouldering multiple myeloma (SMM), just before filing applications for the drug in this indication in Europe and t

News

Daiichi Sankyo partners Alteogen on subcutaneous Enhertu

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu.

News

AZ confirms China president has been detained

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after confirming he was under investigation last week.

Daiichi and AZ pull Dato-DXd filing with FDA and try again

23andMe ends drug development and slashes staff

Autolus bags FDA approval for leukaemia cell therapy

J&J bids to add smouldering myeloma to Darzalex label

Daiichi Sankyo partners Alteogen on subcutaneous Enhertu

AZ confirms China president has been detained

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks